相关实验视频

Updated: Jan 7, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

对抗N-甲基-D-酸盐受体脑炎中中央低通风的危险因素

Xuan Zou^1,2, Xi-Yue Jing³, Guan-En Zhou^1,2

¹Department of Neurology, Tianjin Huanhu Hospital, Tianjin University, Tianjin, China.

Frontiers in immunology

|December 29, 2025

概括

抗N-甲基-D-酸盐受体 (anti-NMDAR) 脑炎中的中心低通风与意识低下和抗体水平较高有关. 对于高风险患者来说,早期监测和干预至关重要.

科学领域:

神经学神经学
免疫学免疫学免疫学
关键护理医学关键护理医学

背景情况:

抗N-甲基-D-酸盐受体 (anti-NMDAR) 脑炎是一种严重的自身免疫神经系统疾病.
中枢低通风是一个关键的并发症,可以导致这些患者的显著发病率和死亡率.
确定中心低通风的危险因素对于及时管理和改善患者结果至关重要.

研究的目的:

确定与被诊断患有抗NMDAR脑炎的患者中中央低通风发展相关的关键风险因素.
分析中心低通风和没有中心低通风患者的临床和实验室数据,以确定预测因素.
为监测和管理风险患者提供基于证据的建议.

主要方法:

在2020年1月至2025年1月期间住院的抗NMDAR脑炎患者进行了一项回顾性研究.
患者被分为两组:中央低通风患者和没有中心低通风患者.
使用统计分析,包括单变量和多变量逻辑回归,以确定独立的风险因素.

主要成果:

经历中央低通风的患者表现出更高的非自愿运动,更低的格拉斯哥昏迷表 (GCS) 评分,以及脑脊液 (CSF) 抗体标位升高.
多变量逻辑回归确定了较低的入院GCS得分 (OR:0.556) 和较高的CSF抗体标位 (OR:<0.001) 作为中央低通风的独立预测因素.
这些发现突出了意识受损和高抗体水平与呼吸系统损害之间的显著关联.

结论:

意识障碍 (通过低GCS得分表明) 和高的CSF抗体标位是抗NMDAR脑炎中中央低通风的重要危险因素.
对于高危人群,建议密切监测呼吸状况,定期进行血液气体分析,及时提供呼吸支持和免疫治疗.
这些措施对于减轻与中心低通风相关的风险和改善抗NMDAR脑炎患者的治疗结果至关重要.

关键词:

抗N-甲基-D-酸盐受体脑炎中央低通风中心的低通风.大脑脊髓液抗体标位意识障碍意识障碍意识障碍有关风险因素的风险因素.

更多相关视频

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

Published on: January 9, 2018

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

相关概念视频

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: